Addressing GI Health Through the Bidirectional Modulation of the Gut-Brain Axis With Herbal Extracts: A Narrative Review – PubMed Black Hawk Supplements

Abstract

Functional gastrointestinal disorders (FGIDs) refer to a group of disorders with chronic symptoms, such as abdominal pain, dysphagia, dyspepsia, diarrhea, constipation, and bloating. Among these, functional constipation significantly impacts the quality of life and is linked with comorbidities, such as anxiety and depression. The exact pathophysiology remains unclear despite the widespread occurrence. Research suggests that the gut-brain axis plays a role in FGIDs. Disruptions in the bidirectional communication between the brain and gastrointestinal (GI) tract contribute to GI symptoms and mood disturbances. The incomplete understanding of FGID pathophysiology has led to limited treatment options. Traditional treatments often focus on single symptoms and come with side effects, prompting the need for alternative approaches that address both GI and psychological components. Alternative approaches including herbal supplements offer a natural alternative to conventional medicine by promoting regularity and gut health. Abelmoschus esculentus L. or okra has a history of use in traditional medicine. Bioactive compounds such as polysaccharides and fibers found in okra offer gastroprotective benefits. Withania somnifera is a plant commonly referred to as ashwagandha. The plant root has been used for its health-promoting effects. Research supports the use of W. somnifera to help with stress and sleep. Digexin is a herbal supplement combining W. somnifera (ashwagandha) and A. esculentus (okra). It has shown promise in improving both GI regularity and mood by modulating the gut-brain axis. Clinical studies support the potential of a novel herbal supplement that aids in the management of FGIDs. This narrative review looks at FGIDs, etiologies, current treatment, and possible therapeutic supplements to aid in symptom management.

Keywords: functional constipation; functional gastrointestinal disorder; gut health; gut-brain axis; gut-brain connection.

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: The authors note that they have received research and educational funding from companies within the foods, beverages, and dietary supplement industries. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Similar articles

• A blend of Withania somnifera (L.) Dunal root and Abelmoschus esculentus (L.) Moench fruit extracts relieves constipation and improves bowel function: A proof-of-concept clinical investigation.

  Punukollu RS, Chadalawada AK, Siddabattuni K, Gogineni NT. Punukollu RS, et al. J Ethnopharmacol. 2024 Jan 10;318(Pt B):116997. doi: 10.1016/j.jep.2023.116997. Epub 2023 Aug 4. J Ethnopharmacol. 2024. PMID: 37543151 Clinical Trial.

• Is there a causal link between psychological disorders and functional gastrointestinal disorders?

  Koloski N, Holtmann G, Talley NJ. Koloski N, et al. Expert Rev Gastroenterol Hepatol. 2020 Nov;14(11):1047-1059. doi: 10.1080/17474124.2020.1801414. Epub 2020 Aug 17. Expert Rev Gastroenterol Hepatol. 2020. PMID: 32715790 Review.

• The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions.

  Tait C, Sayuk GS. Tait C, et al. Eur J Intern Med. 2021 Feb;84:1-9. doi: 10.1016/j.ejim.2020.12.023. Epub 2021 Jan 7. Eur J Intern Med. 2021. PMID: 33423906 Review.

• Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: ashwagandha.

  Ven Murthy MR, Ranjekar PK, Ramassamy C, Deshpande M. Ven Murthy MR, et al. Cent Nerv Syst Agents Med Chem. 2010 Sep 1;10(3):238-46. doi: 10.2174/1871524911006030238. Cent Nerv Syst Agents Med Chem. 2010. PMID: 20528765 Review.

• Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.

  Singh R, Zogg H, Ghoshal UC, Ro S. Singh R, et al. Front Pharmacol. 2022 Jan 25;13:808195. doi: 10.3389/fphar.2022.808195. eCollection 2022. Front Pharmacol. 2022. PMID: 35145413 Free PMC article. Review.

Publication types